Starting with Choline Alfoscerate, a brain function improving agent, the benefit reassessment, which has been in full swing since last year, has risen again this year. On the 11th, HIRA's Drug Reimbursement Evaluation Committee confirmed the items subject to salary revaluation in 2022 and 2023. Detailed items will be released through the Health Insurance Policy Committee. However, despite the HIRA notice, the target item was released to the media a few hours later.

Six drugs, including Godex, were included in 2022 and eight drugs, including Hyaluronic acid eye drops, in 2023. Since media reports, the HIRA has not made any opinions on this. Perhaps this is because the items subject to re-evaluation match